Open AccessIndependent validation of the PAM50-based chemo-endocrine score (CES) in hormone receptor-positive HER2-positive breast cancer treated with neoadjuvant anti-HER2-based therapy
Author(s) -
T. Pascual,
Aranzazu Fernández-Martínez,
M. Tanioka,
M.V. Dieci,
S. Pernas,
J. Gavila,
V. Guarnieri,
J. Cortes,
P. Villagrasa,
N. Chic,
M. Vidal,
B. Adamo,
M. Muñoz,
G. Griguolo,
A. Llombart,
P. Conte,
M. Oliveira,
B. Conte,
L. Pare,
P. Galvan,
L.A. Carey,
C.M. Perou,
A. Prat
Publication year - 2021
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/0fn5-pw90
Subject(s) - oestrogen receptor , oncology , breast cancer , medicine , endocrine system , hormone receptor , cancer , neoadjuvant therapy , hormone